THRB and metabolic dysfunction-associated steatohepatitis: In March 2024, the thyroid hormone receptor beta (THR-β) selective agonist resmetirom gained conditional approval from FDA as the first pharmacologic treatment for NASH patients with moderate-to-advanced liver fibrosis (FDA, 2024).